Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

An Open-Label Phase II Feasibility Study for the Use of Ublituximab in Adults With Down Syndrome Regression Disorder

4. září 2026 aktualizováno: Jonathan Santoro

The goal of this clinical trial is to evaluate whether the monoclonal antibody ublituximab can treat Down Syndrome Regression Disorder (DSRD) by assessing its safety, tolerability, and preliminary efficacy in affected individuals. This study is conducted in adults aged 18-40 years with Down syndrome who have DSRD and have had an inadequate or partial response to first-line therapies.

The main questions it aims to answer are:

  • Does ublituximab demonstrate acceptable safety and tolerability, as measured by treatment-emergent adverse events from baseline through Week 24?
  • Does ublituximab lead to improvement in cognitive, neuropsychiatric, motor, and functional outcomes from baseline to Weeks 12 and 24?

This is a single-arm study, so there is no comparison group.

Participants will:

  • Receive two intravenous infusions of ublituximab (150 mg on Day 1 and 450 mg on Day 15)
  • Attend study visits at Screening, Baseline (Day 1) , Week 2 (Day 15), Week 3, Week 6, Week 12, and Week 24
  • Undergo clinical assessments, including neurological and physical exams and safety monitoring labs throughout the study
  • Complete cognitive, behavioral, and functional evaluations at Baseline, Week 12, and Week 24
  • Provide blood samples for safety monitoring and research biomarker analyses

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Typ studie

Intervenční

Zápis (Odhadovaný)

20

Fáze

  • Fáze 2

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní záloha kontaktů

Studijní místa

  • Spojené státy
    • California
      • Los Angeles, California, Spojené státy, 90027
        • Children's Hospital Los Angeles
        • Kontakt:
        • Kontakt:
        • Vrchní vyšetřovatel:
          • Jonathan Santoro, MD

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý

Přijímá zdravé dobrovolníky

Ne

Popis

Inclusion Criteria:

  • Age 18 to 40 years, inclusive at time of consent
  • Diagnosis of Down syndrome (trisomy 21 or translocation type)
  • Diagnosis of possible or probable Down Syndrome Regression Disorder (DSRD) based on 2022 International Consensus Criteria
  • History of partial response or non-response to first-line treatment (e.g., lorazepam, SSRIs, corticosteroids, and/or IVIg). Partial response = 10-50% improvement, Non-response = <10% improvement, Based on BFCRS or NPI-Q after 3 months of treatment.
  • Ability to attend all study visits with a study partner or legally authorized representative
  • Study partner willing to comply with all study procedures
  • Willingness to complete required washout periods for medications that may interfere with the study
  • Highly effective contraception for reproductive participants and partners of childbearing potential.
  • Study partner/LAR sufficiently proficient in English to complete assessments.

Exclusion Criteria:

  • Mosaic Down syndrome
  • Weight < 40 kg at screening
  • Pregnancy or breastfeeding
  • Current or past tobacco smoking
  • Poor venous access or inability to comply with IV procedures
  • Use of IVIg within 8 weeks prior to baseline
  • Use of immunosuppressive drugs within 12 weeks prior to baseline
  • Prior treatment with anti-CD20 or B-cell therapies within required washout unless B-cell recovery criteria are met
  • Other immunosuppressive biologics within 24 months.
  • Any prior use of chemotherapeutic agents (e.g., methotrexate, cyclophosphamide)
  • History of solid organ transplant
  • Recent receipt of blood or plasma products (≤30 days)
  • Clinically significant cardiac disease, clotting disorder, or other serious medical condition
  • Active or chronic infection of clinical significance (including HBV, HCV, TB, HIV per protocol criteria)
  • History of malignancy
  • Abnormal screening labs indicating unacceptable risk
  • Receipt of live or live-attenuated vaccines within 4 weeks prior to treatment
  • Untreated thyroid disease (hypo- or hyperthyroidism)
  • History of moyamoya syndrome or stroke
  • Wards of the state
  • Employees or students of Children's Hospital Los Angeles (CHLA)
  • Prior neurosurgical intervention (exceptions for longstanding shunts)
  • Current investigational therapy/prohibited medications
  • Detailed HBV, HCV, and TB criteria
  • Requirement for B-cell recovery >50 cells/μL after prior anti-CD20 therapy.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: N/A
  • Intervenční model: Přiřazení jedné skupiny
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Ublituximab
Participants assigned to the Ublituximab arm will receive a fixed two-dose intravenous regimen consisting of 150 mg on Day 1 and 450 mg on Day 15. All participants will be followed for 24 weeks with regular safety monitoring, clinical assessments, and evaluation of cognitive, neuropsychiatric, and functional outcomes.
Lék: Ublituximab
Participants assigned to the Ublituximab arm will receive a fixed two-dose intravenous regimen consisting of 150 mg on Day 1 and 450 mg on Day 15. All participants will be followed for 24 weeks with regular safety monitoring, clinical assessments, and evaluation of cognitive, neuropsychiatric, and functional outcomes.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Total AEs on Ublituximab
Časové okno: Baseline through Week 24
Safety will be evaluated by the incidence, type, severity (graded per CTCAE v5.0), and relationship of treatment-emergent adverse events (AEs) occurring after the first dose of ublituximab. Tolerability will be assessed by the proportion of participants completing both doses and follow-up without dose modifications, interruptions, or discontinuation due to AEs.
Baseline through Week 24

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in Scores for Adaptive Behavior using VABS-3 Composite and Domain Survey
Časové okno: Baseline, Week 12, and Week 24
Change from baseline in adaptive functioning measured by the Vineland Adaptive Behavior Scales, Third Edition (VABS-3), including communication, daily living skills, socialization, and maladaptive behavior domains as reported by caregivers.
Baseline, Week 12, and Week 24
Change in Scores for Catatonia Severity using Bush-Francis Catatonia Rating Scale
Časové okno: Baseline, Week 12, and Week 24

Change from baseline in catatonia symptoms measured by the Bush-Francis Catatonia Rating Scale (BFCRS), with decreases in total score indicating improvement in symptom severity.

0 (no catatonia) - 45 (Severe Catatonia)
Baseline, Week 12, and Week 24
Change in Score for Neuropsychiatric Symptoms using Neuropsychiatric Inventory Questionnaire (NPI-Q)
Časové okno: Baseline, Week 12, and Week 24
Change from baseline in neuropsychiatric symptom burden as measured by the Neuropsychiatric Inventory Questionnaire (NPI-Q), a caregiver-reported assessment of symptom frequency and severity across behavioral domains.
Baseline, Week 12, and Week 24
Change in Motor Function (Timed 25-Foot Walk)
Časové okno: Baseline, Week 12, and Week 24
Change from baseline in time (seconds) required to complete the Timed 25-Foot Walk (T25-FW), reflecting gait speed and motor function, with decreased time indicating improvement.
Baseline, Week 12, and Week 24
Change in Global Clinical Status Using Clinician Global Impression of Change-Down Syndrome (CGIC-DS)
Časové okno: Baseline, Week 12, and Week 24
Change from baseline in global clinical status assessed using the Clinician Global Impression of Change-Down Syndrome (CGIC-DS), a Down syndrome-adapted clinician-rated instrument. The Baseline version generates a Clinical Global Impression-Severity (CGI-S) rating to assess overall illness severity, and the Follow-up version generates a Clinical Global Impression-Improvement (CGI-I) rating to assess clinical change relative to baseline. CGI-S scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill), while CGI-I scores range from 1 (very much improved) to 7 (very much worse). Assessments will be conducted at Baseline, Week 12, and Week 24.
Baseline, Week 12, and Week 24
Change in Global Clinical Status Using Clinical Global Impression-Severity (CGI-S) and Clinical Global Impression-Improvement (CGI-I) Scores Derived from the Clinician Global Impression of Change-Down Syndrome (CGIC-DS)
Časové okno: Baseline, Week 12, and Week 24
Change from baseline in global clinical status measured using CGI-S and CGI-I ratings derived from the Clinician Global Impression of Change-Down Syndrome (CGIC-DS). CGI-S assesses overall illness severity, and CGI-I assesses improvement or worsening relative to baseline. Assessments will be conducted at Baseline, Week 12, and Week 24. Lower CGI-S scores indicate reduced illness severity, and lower CGI-I scores indicate greater clinical improvement.
Baseline, Week 12, and Week 24
Change in Participant Quality of Life Using Pediatric Quality of Life Inventory (PedsQL) Parent Report
Časové okno: Baseline, Week 12, and Week 24
Change from baseline in participant quality of life measured by the Pediatric Quality of Life Inventory (PedsQL) Parent Report. This caregiver-reported assessment evaluates health-related quality of life across physical functioning, emotional functioning, social functioning, and work/studies functioning domains. Higher scores indicate better quality of life and functional status. Assessments will be conducted at Baseline, Week 12, and Week 24.
Baseline, Week 12, and Week 24
Change in Caregiver and Family Functioning Using Pediatric Quality of Life Inventory Family Impact Module (PedsQL-FIM)
Časové okno: Baseline to Week 24
Change from baseline in caregiver and family functioning measured by the Pediatric Quality of Life Inventory Family Impact Module (PedsQL-FIM). This caregiver-reported assessment evaluates the impact of the participant's condition on caregiver well-being and family functioning across physical, emotional, social, cognitive, communication, daily activities, and family relationship domains. Higher scores indicate better caregiver quality of life, improved family functioning, and less negative impact on the family. Assessments will be conducted at Baseline, Week 12, and Week 24.
Baseline to Week 24
Change in Communication Ability Using Observer-Reported Communication Ability (ORCA) Measure
Časové okno: Baseline, Week 12, and Week 24
Change from baseline in communication abilities measured by the Observer-Reported Communication Ability (ORCA) Measure, a caregiver-reported assessment of expressive and receptive communication skills. The ORCA evaluates verbal communication, use of gestures, social communication, requesting, conversation, comprehension, and functional communication abilities in everyday settings. Higher scores indicate greater communication ability and improved functional communication.
Baseline, Week 12, and Week 24
Change in Caregiver and Family Functioning Using Pediatric Quality of Life Inventory Family Impact Module (PedsQL-FIM)
Časové okno: Baseline, Week 12, and Week 24
Change from baseline in caregiver and family functioning measured by the Pediatric Quality of Life Inventory Family Impact Module (PedsQL-FIM). This caregiver-reported assessment evaluates the impact of the participant's condition on caregiver well-being and family functioning across physical, emotional, social, cognitive, communication, daily activity, and family relationship domains. Higher scores indicate better caregiver and family functioning and lower family burden.
Baseline, Week 12, and Week 24
Change in Obsessive-Compulsive Symptom Severity Using Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
Časové okno: Baseline, Week 12, and Week 24
Change from baseline in obsessive-compulsive symptom severity measured by the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS), a clinician-administered assessment of obsessions and compulsions. The CY-BOCS evaluates symptom severity across domains including time occupied, interference, distress, resistance, and degree of control. Higher scores indicate greater obsessive-compulsive symptom severity, and decreases in total score indicate improvement.
Baseline, Week 12, and Week 24

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in Peripheral B-Cell Counts Following Ublituximab Treatment
Časové okno: Baseline, Week 2, Week 6, Week 12, and Week 24
Change from baseline in peripheral B-cell populations measured by high-sensitivity flow cytometry, including absolute B-cell counts and percentages of CD19+ and CD20+ B cells. Exploratory analyses will evaluate the extent and duration of B-cell depletion following ublituximab treatment and the association between B-cell depletion and clinical outcomes.
Baseline, Week 2, Week 6, Week 12, and Week 24
Change in Inflammatory Cytokine Profiles
Časové okno: Baseline and Week 24
Change from baseline in circulating inflammatory cytokine concentrations measured using multiplex immunoassay platforms. Cytokines and related inflammatory biomarkers will be evaluated to characterize immunologic changes associated with ublituximab treatment and Down Syndrome Regression Disorder (DSRD).
Baseline and Week 24
Change in Plasma Proteomic Signatures
Časové okno: Baseline and Week 24
Change from baseline in plasma proteomic profiles measured using high-throughput proteomic platforms. Exploratory analyses will identify protein expression patterns associated with DSRD and evaluate molecular changes occurring following ublituximab treatment.
Baseline and Week 24
Change in Plasma Metabolomic Profiles
Časové okno: Baseline and Week 24
Change from baseline in plasma metabolomic signatures measured using mass spectrometry-based metabolomic analyses. Exploratory analyses will evaluate treatment-associated changes in metabolic pathways and identify biomarkers associated with disease activity and therapeutic response.
Baseline and Week 24
Change in Interferon Signaling and Transcriptomic Profiles
Časové okno: Baseline and Week 24
Change from baseline in whole-blood transcriptomic signatures, including interferon-related gene expression profiles, measured from RNA biospecimens. Exploratory analyses will characterize molecular pathways associated with DSRD and assess the impact of B-cell depletion therapy on interferon signaling and other transcriptional biomarkers.
Baseline and Week 24
Change in Global Autoantibody Profiles
Časové okno: Baseline and Week 24
Change from baseline in circulating autoantibody profiles measured using high-throughput autoantibody profiling technologies. Exploratory analyses will evaluate changes in autoantibody repertoires following ublituximab treatment and assess associations wi
Baseline and Week 24
Change in Biomarkers of Neurodegeneration and Neuroinflammation
Časové okno: Baseline and Week 24
Change from baseline in plasma biomarkers of neurodegeneration and neuroinflammation, including neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase L1 (UCHL1), total tau, and other validated biomarkers. Exploratory analyses will evaluate relationships between biomarker changes and clinical outcomes following ublituximab treatment.
Baseline and Week 24

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Jonathan Santoro

Vyšetřovatelé

  • Vrchní vyšetřovatel: Jonathan Santoro, MD, Children's Hospital Los Angeles

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. října 2026

Primární dokončení (Odhadovaný)

1. října 2030

Dokončení studie (Odhadovaný)

1. prosince 2030

Termíny zápisu do studia

První předloženo

4. září 2026

První předloženo, které splnilo kritéria kontroly kvality

4. září 2026

První zveřejněno (Aktuální)

10. září 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

10. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

4. září 2026

Naposledy ověřeno

1. září 2026

Více informací

Termíny související s touto studií

Klíčová slova

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • CHLA-26-00158

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit